KLP Kapitalforvaltning AS Makes New Investment in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

KLP Kapitalforvaltning AS bought a new stake in shares of Apellis Pharmaceuticals, Inc. ( NASDAQ:APLS – Free Report ) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 15,800 shares of the company’s stock, valued at approximately $504,000.

Several other hedge funds have also made changes to their positions in the company. Xponance Inc. increased its stake in shares of Apellis Pharmaceuticals by 5.



6% during the fourth quarter. Xponance Inc. now owns 14,072 shares of the company’s stock valued at $449,000 after buying an additional 749 shares during the period.

EverSource Wealth Advisors LLC grew its holdings in Apellis Pharmaceuticals by 2,707.1% during the 4th quarter. EverSource Wealth Advisors LLC now owns 786 shares of the company’s stock worth $25,000 after acquiring an additional 758 shares in the last quarter.

Signaturefd LLC increased its position in Apellis Pharmaceuticals by 357.2% during the 4th quarter. Signaturefd LLC now owns 1,175 shares of the company’s stock valued at $37,000 after purchasing an additional 918 shares during the period.

Toronto Dominion Bank raised its holdings in shares of Apellis Pharmaceuticals by 4.2% in the 3rd quarter. Toronto Dominion Bank now owns 25,622 shares of the company’s stock valued at $739,000 after purchasing an additional 1,022 shares in the last quarter.

Finally, US Bancorp DE lifted its position in shares of Apellis Pharmaceuticals by 70.0% in the 4th quarter. US Bancorp DE now owns 3,223 shares of the company’s stock worth $103,000 after purchasing an additional 1,327 shares during the period.

96.29% of the stock is currently owned by hedge funds and other institutional investors. Analysts Set New Price Targets APLS has been the topic of several research reports.

Scotiabank lifted their price objective on shares of Apellis Pharmaceuticals from $30.00 to $31.00 and gave the company a “sector perform” rating in a report on Wednesday.

Wedbush cut their price target on Apellis Pharmaceuticals from $30.00 to $29.00 and set a “neutral” rating on the stock in a report on Monday, March 3rd.

HC Wainwright reissued a “buy” rating and issued a $57.00 price target on shares of Apellis Pharmaceuticals in a research report on Monday, March 3rd. The Goldman Sachs Group cut their target price on Apellis Pharmaceuticals from $36.

00 to $32.00 and set a “neutral” rating on the stock in a research note on Monday, March 3rd. Finally, Royal Bank of Canada reduced their target price on shares of Apellis Pharmaceuticals from $26.

00 to $25.00 and set a “sector perform” rating for the company in a report on Monday, March 3rd. Eight investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company.

According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $45.59.

Insiders Place Their Bets In other Apellis Pharmaceuticals news, insider Caroline Baumal sold 2,816 shares of the firm’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $33.81, for a total transaction of $95,208.

96. Following the completion of the transaction, the insider now directly owns 55,560 shares of the company’s stock, valued at approximately $1,878,483.60.

This trade represents a 4.82 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link .

Also, General Counsel David O. Watson sold 3,323 shares of Apellis Pharmaceuticals stock in a transaction that occurred on Wednesday, January 22nd. The shares were sold at an average price of $30.

43, for a total transaction of $101,118.89. Following the sale, the general counsel now owns 144,994 shares of the company’s stock, valued at approximately $4,412,167.

42. The trade was a 2.24 % decrease in their ownership of the stock.

The disclosure for this sale can be found here . In the last 90 days, insiders sold 66,054 shares of company stock valued at $1,952,719. 6.

80% of the stock is owned by company insiders. Apellis Pharmaceuticals Stock Down 2.1 % APLS stock opened at $22.

52 on Friday. The company has a quick ratio of 3.73, a current ratio of 4.

36 and a debt-to-equity ratio of 1.91. Apellis Pharmaceuticals, Inc.

has a 52 week low of $21.70 and a 52 week high of $58.12.

The stock has a market capitalization of $2.83 billion, a PE ratio of -11.09 and a beta of 0.

85. The firm has a 50 day moving average of $26.42 and a 200 day moving average of $29.

16. Apellis Pharmaceuticals ( NASDAQ:APLS – Get Free Report ) last posted its quarterly earnings data on Friday, February 28th. The company reported ($0.

29) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.08.

Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%.

The business had revenue of $212.50 million during the quarter, compared to the consensus estimate of $197.92 million.

During the same period in the previous year, the firm posted ($0.73) earnings per share. The business’s revenue for the quarter was up 45.

2% compared to the same quarter last year. Sell-side analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.

7 earnings per share for the current year. About Apellis Pharmaceuticals ( Free Report ) Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).

Further Reading Want to see what other hedge funds are holding APLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Apellis Pharmaceuticals, Inc. ( NASDAQ:APLS – Free Report ).

Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter ..